$-0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

February 15, 2018 - By Adrian Mccoy

 $ 0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

Analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report $-0.11 EPS on March, 14.They anticipate $0.21 EPS change or 65.63 % from last quarter’s $-0.32 EPS. After having $-0.43 EPS previously, Xenon Pharmaceuticals Inc.’s analysts see -74.42 % EPS growth. The stock decreased 1.89% or $0.07 during the last trading session, reaching $3.63. About 11,148 shares traded. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has declined 39.94% since February 15, 2017 and is downtrending. It has underperformed by 56.64% the S&P500.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Ratings Coverage

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. As per Monday, September 11, the company rating was maintained by Jefferies. As per Tuesday, August 11, the company rating was maintained by Canaccord Genuity. Jefferies reinitiated the shares of XENE in report on Friday, October 30 with “Buy” rating. The rating was upgraded by Zacks on Wednesday, August 19 to “Sell”. The rating was initiated by Stifel Nicolaus with “Buy” on Friday, October 21. The firm has “Buy” rating by Jefferies given on Friday, August 4. The rating was upgraded by Zacks on Tuesday, August 11 to “Sell”. Zacks downgraded the stock to “Sell” rating in Wednesday, September 2 report. The firm earned “Buy” rating on Monday, June 12 by Jefferies. As per Monday, March 13, the company rating was reinitiated by Jefferies.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $65.33 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

More notable recent Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news were published by: Globenewswire.com which released: “Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update” on March 08, 2017, also Globenewswire.com with their article: “Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare …” published on April 26, 2017, Marketwatch.com published: “Xenon Pharmaceuticals Inc.” on October 21, 2016. More interesting news about Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were released by: Globenewswire.com and their article: “Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial” published on October 17, 2017 as well as Globenewswire.com‘s news article titled: “Xenon Pharmaceuticals Outlines Key Milestones for 2017” with publication date: January 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: